In a small international trial, novel oral medication muvalaplin lowered Lp(a)
November 18, 2024
November 18, 2024
DALLAS, Texas, Nov. 18 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease.
Muvalaplin is a small molecule inhibitor that prevents the bonding of the two protein components that combine to make Lp(a). There are no currently FDA-approv . . .
Research Highlights:
The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease.
Muvalaplin is a small molecule inhibitor that prevents the bonding of the two protein components that combine to make Lp(a). There are no currently FDA-approv . . .